UNSPSC 51162020: Dyphylline/guaifenesin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162020 Dyphylline/guaifenesin, a Commodity code, shows misalignment between its nominal scope and recent state and local procurement activity. The code itself names a specific bronchodilator and expectorant combination product, but the four recent solicitations posted since January 2026 focus on naloxone procurement, on-site pharmacy services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products — none of which involve dyphylline/guaifenesin specifically. The code carries little relevant procurement activity under its stated commodity definition.

Recent opportunities reflect broader pharmaceutical procurement and pharmacy services strategies across state and local health agencies rather than purchases of this particular drug formulation. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems (due July 26, 2023); Hall County, Georgia issued an RFQ/P for on-site pharmacy services at its government health center (due June 4, 2026); the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription programs (posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (due March 26, 2026). State and local buyers are pursuing pharmacy benefit management, generic drug sourcing, and emergency medication stock rather than branded or generic dyphylline/guaifenesin products. Firms pursuing this code should verify whether their actual service or product mix aligns with it, as the recent record suggests the code may be misapplied to these opportunities or that dyphylline/guaifenesin carries insufficient procurement demand to generate reliable bid activity.